BioMark Diagnostics Inc. BMKDF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -81.91% | -81.25% | -81.82% | -82.21% | 0.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -81.91% | -81.25% | -81.82% | -82.21% | 0.71% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -81.91% | -81.25% | -81.82% | -82.21% | 0.71% |
| SG&A Expenses | -19.88% | -54.67% | 34.63% | -34.91% | -47.85% |
| Depreciation & Amortization | -0.41% | -74.95% | 142.11% | 47.42% | 72.04% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.01% | -41.21% | 58.46% | -21.67% | -34.05% |
| Operating Income | -10.77% | 38.60% | -76.76% | 17.61% | 36.34% |
| Income Before Tax | 12.47% | 50.54% | -14.05% | 12.91% | 33.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 12.47% | 50.54% | -14.05% | 12.91% | 33.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.47% | 50.54% | -14.05% | 12.91% | 33.98% |
| EBIT | -10.77% | 38.60% | -76.76% | 17.61% | 36.34% |
| EBITDA | -10.77% | 38.94% | -77.91% | 17.75% | 36.63% |
| EPS Basic | 13.79% | 50.00% | -766.67% | 25.00% | 42.00% |
| Normalized Basic EPS | 16.67% | 47.06% | -700.00% | 25.00% | 41.94% |
| EPS Diluted | 13.79% | 50.00% | -766.67% | 25.00% | 42.00% |
| Normalized Diluted EPS | 16.67% | 47.06% | -700.00% | 25.00% | 41.94% |
| Average Basic Shares Outstanding | 1.21% | 0.00% | -88.13% | 15.63% | 15.63% |
| Average Diluted Shares Outstanding | 1.21% | 0.00% | -88.13% | 15.63% | 15.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |